NMN vs NR: does either one actually raise your NAD+ — and does it matter?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme required for several hundred enzymatic reactions in the body — mitochondrial energy production, DNA repair via PARP enzymes, and the sirtuin family of proteins tied to cellular stress resistance. NAD+ levels fall with age; this decline is one of the more consistently replicated findings in aging biology, observed across tissue types and species, though the exact rate and pattern vary by the tissue and method used to measure it.

That decline is the premise behind an entire supplement category. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two most-studied dietary precursors marketed to restore NAD+. Both are legal, over-the-counter, and neither is an approved drug for any indication. What's worth being precise about upfront: that NAD+ falls with age is well established. That taking a precursor to raise it back up meaningfully changes the outcomes people actually care about — strength, cognition, healthspan — is the part still being tested, and the evidence for that second claim is considerably thinner than the marketing around it suggests.

NMN sits one enzymatic step from NAD+ in what's called the salvage pathway — the route the body uses to recycle NAD+ from its breakdown products, rather than building it from scratch from dietary tryptophan. Once NMN is inside a cell, one of three NMNAT enzymes (NMNAT1, NMNAT2, or NMNAT3, depending on the cell compartment) converts it directly to NAD+.

NR takes the same route but starts one step earlier. It must first be phosphorylated into NMN by nicotinamide riboside kinase (NRK1 or NRK2) before it can reach that same NMNAT reaction. In other words, NR is upstream of NMN in this pathway, not a separate parallel one — both molecules converge on an identical final step. How intact NMN itself crosses into cells has been genuinely debated in the literature: some work points to a dedicated transporter identified in mouse gut tissue, while other groups argue NMN is broken down to NR outside the cell and re-enters through NR's own transport route before being rebuilt into NMN inside the cell. That question is unresolved — it is an open mechanistic debate, not a settled detail, and it's part of why absorption claims for either supplement should be read cautiously.

Most of the NMN-vs-NR debate online is built on separate trials of each molecule, run in different populations with different doses — not a true comparison. The most direct evidence available is a 2026 Nature Metabolism trial that dosed all three candidate molecules in the same study, in the same population, at the same time. Sixty-five healthy adults (average age 34.7) were randomized to nicotinamide riboside (1 g/day), nicotinamide mononucleotide (1 g/day), plain nicotinamide (0.5 g/day), or placebo for 14 days.^[1]

NR and NMN each raised circulating NAD+ by roughly two-fold — functionally identical to each other. Nicotinamide produced only a transient spike at four hours and no sustained increase by day 14. The trial also reported that both NR and NMN shifted gut microbial short-chain fatty acid production, a secondary, exploratory finding worth noting but not yet established as clinically meaningful — and worth flagging that this trial was conducted by Nestlé Health Science, so read the funding source alongside the result.^[1]

In a 60-day, multicenter, dose-dependent RCT of 80 healthy middle-aged adults (300, 600, or 900 mg/day NMN vs placebo), blood NAD+ rose significantly in all treated groups by day 30 and day 60 (p ≤ 0.001), with the highest concentrations in the 600 mg and 900 mg groups, and walking-distance performance improved significantly across all dosed groups versus placebo (p < 0.01). No safety signal was seen.^[2]

In a separate 12-week, double-blind RCT of 60 older adults given 250 mg/day, the NMN group showed significantly higher blood NAD+, a significantly shorter 4-meter walking time versus placebo, and improved sleep-quality subscores (lower "daytime dysfunction" and lower global Pittsburgh Sleep Quality Index) versus placebo.^[3]

A third 12-week RCT of 36 middle-aged adults at 250 mg/day found NAD+-pathway metabolites rose significantly, and arterial stiffness (pulse wave velocity) trended downward by 25.1 ± 14.5 cm/s in the NMN group — but this did not reach statistical significance for the group as a whole (p = 0.097). It reached significance only in a subgroup with elevated BMI or blood glucose. That subgroup result is hypothesis-generating, not confirmatory, and should be read that way.^[4]

Doses used in the human trials reviewed here range from 250 mg/day (used in two separate 12-week RCTs) to 300–900 mg/day (a 60-day, three-arm dose-dependent RCT) up to a single 1,250 mg/day dose sustained for 4 weeks in a dedicated safety trial.^[2][3][4][5] Across all of these, no trial reported a serious adverse event attributable to NMN, and standard hematology, biochemistry, and body-composition panels stayed within normal ranges.^[5]

Two limits are worth stating plainly rather than glossing over. First, no controlled human trial identified for this article ran longer than about 12 weeks — there is no published long-term (6-month-plus) safety or efficacy data in humans. Second, most trials are small by clinical-trial standards (31 to 80 participants), which limits their power to detect smaller or less common effects, whether beneficial or adverse. NMN in pregnancy, breastfeeding, and in people on prescription medications that interact with NAD+ metabolism has essentially no dedicated human safety data.

There is no official clinical dosing guideline for NMN — it is regulated as a dietary supplement, not an approved drug, so no health authority has set a recommended daily amount. Based on the doses that produced a statistically significant rise in blood NAD+ in the trials above, most effective human dosing has clustered in the 250–900 mg/day range, typically taken once daily with food. In the largest dose-ranging trial available, NAD+ concentrations were highest in the 600 mg and 900 mg groups, with little apparent additional benefit beyond that range — though higher doses have not been formally tested for efficacy, only for safety (1,250 mg/day, single dose, 4 weeks).^[2][5]

This is general information from the published literature, not a personal recommendation. Talk to your own healthcare provider before starting NMN or any NAD+ precursor, particularly if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medication.

If NMN's evidence profile — reliable NAD+ elevation, an honest gap on muscle and strength outcomes, and a well-tolerated but short-term-only safety record — fits what you're looking for, product quality is the next variable that matters. NAD+ precursor supplements are not standardized the same way pharmaceuticals are, and label accuracy varies by manufacturer the same way it does across the creatine market. Look for a named raw-material source and, where available, third-party testing.

Peak Human's Beta-NMN capsules are available on both peakhumanshop.com and Amazon. You can also browse the full evidence-based NAD+ precursor category or the wider supplements shop for other options Dr. Goel's team has vetted.

NMN and NR are functionally tied on the one thing they're both built to do — raise blood NAD+. That part of the marketing rivalry is settled by the best data available. What's not settled is whether raising NAD+ this way meaningfully moves the outcomes most people actually buy these supplements for: strength, muscle, and long-term healthspan. On muscle and physical function specifically, the 2025 meta-analysis evidence says no, not yet. Treat NMN as a well-tolerated, NAD+-raising supplement with a real but still-developing evidence base — not a finished longevity intervention.